Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian stock markets shed gains
Tue, 20 Dec 11:30 am

Indian stock markets indices could not hold on to their early morning gains and moved into the negative zone during the previous two hours of trade. All sectoral indices were trading weak except for FMCG, healthcare and IT stocks.

The BSE-Sensex is trading down by 40 points and NSE-Nifty is trading down by 15 points. BSE Mid Cap and BSE Small Cap indices are trading weak by 0.9% each. The rupee is trading at 53.06 to the US dollar.

Pharma stocks are mainly trading in the green led by Orchid Chemicals and Stride Arcolabs. As per a leading financial daily, Dr Reddy's Laboratories has exited the business of drug research on diabetes and cardiovascular problems. It may be noted here that pharma companies are shying away from conducting new drug research as the costs of conducting clinical trials has gone up. Dr Reddy's too is citing the same reason for this move. The pharma company was in the process of developing an anti-diabetes drug "Balaglitazone" for diabetes and the research had reached phase-3 where it was discontinued. Another diabetes drug "CETP Inhibitor" is in phase-2 but had to be kept aside. As per industry experts, the diabetes segment is highly regulated. It requires cardio trials over a period of time to prove the side-effects that drugs in this segment may have. This makes research even more costlier for diabetes drugs.

Banking stocks are trading weak today led by UCO Bank and Union Bank. As per a leading financial daily, the Reserve Bank of India has asked all banks to comply with the Know Your Customer (KYC) norms or Anti- Money Laundering standards. In the event of non-compliance with these, the banks will have to face penalty under Banking Regulation Act, 1949. All banks have to prepare a risk profile of their customers and perform due diligence on the customers with higher risks. The Reserve Bank Of India (RBI) stated that for this, the Indian Banks' Association has taken steps towards assessment of money laundering and financial terror and risk in the sector. The IBA provides for a probable list of high risk customers, products, services and geographies that may prove to be useful to the banks.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian stock markets shed gains". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.